Association of Saquinavir Plasma Concentrations with Side Effects but Not with Antiretroviral Outcome in Patients Infected with Protease Inhibitor-Susceptible Human Immunodeficiency Virus Type 1

অনুরূপ উপাদানগুলি

• Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen
  অনুযায়ী: von Hentig, Nils, অন্যান্য
  প্রকাশিত: (2008)
• Cytochrome P450 3A Inhibition by Atazanavir and Ritonavir, but Not Demography or Drug Formulation, Influences Saquinavir Population Pharmacokinetics in Human Immunodeficiency Virus Type 1-Infected Adults
  অনুযায়ী: von Hentig, Nils, অন্যান্য
  প্রকাশিত: (2009)
• Pharmacokinetics of Saquinavir, Atazanavir, and Ritonavir in a Twice-Daily Boosted Double-Protease Inhibitor Regimen
  অনুযায়ী: von Hentig, Nils, অন্যান্য
  প্রকাশিত: (2007)
• Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation of Established Mutations and Characterization of New Polymorphisms at Codons 208, 211, and 214
  অনুযায়ী: Stürmer, Martin, অন্যান্য
  প্রকাশিত: (2003)
• Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy
  অনুযায়ী: von Hentig, Nils
  প্রকাশিত: (2015)